The pressing issues this morning
The FDA is at a pivotal moment regarding compounded peptides—a topic stirring considerable debate. Meanwhile, Revolution Medicines aims to secure approval for a promising pancreatic cancer treatment backed by robust clinical data.
The FDA panel and its peptide challenge
As the use of synthetic peptides rises in the U.S., an FDA advisory committee convenes to discuss the future of seven specific peptides manufactured by compounding pharmacies. This meeting, occurring today and tomorrow, may lead to tension between experienced FDA scientists, newly appointed panelists with industry connections, and Health and Human Services (HHS) leadership that generally advocates for broader access to these substances.
The push to regulate compounded peptides aims to redirect patients from an unregulated marketplace, yet there are valid concerns about the implications of enhancing access without substantial clinical evidence. Jason Nagata, a pediatric professor at the University of California San Francisco, emphasizes the potential risks: “The key public health question is whether these products should become more widely available before that evidence exists.” He warns that broadening access without solid scientific backing could inadvertently lend legitimacy to products that currently lack verified safety and efficacy.
Revolution Medicines gets a nod for cancer drug
In a positive development for Revolution Medicines, the FDA has accepted their new drug application for daraxonrasib, a therapy targeting metastatic pancreatic cancer. The application is underpinned by promising results from a Phase 3 study, which noted marked improvements in both overall survival and progression-free survival compared to standard chemotherapy, alongside enhancements in patients' quality of life and pain management.
This application benefits from the FDA’s National Priority Voucher pilot program, potentially expediting the review timeline significantly.
GSK secures first lung cancer drug approval
GSK has achieved a milestone with the FDA's approval of Jideytro, marking its entry into the lung cancer treatment space. This drug targets non-small cell lung cancer and is particularly significant as it follows GSK's recent acquisition of Nuvalent for $10.6 billion, completed just last month. The approval, granted ahead of the expected date, covers patients with advanced or metastatic tumors exhibiting ROS1 mutations who have already undergone treatment with ROS1 kinase inhibitors. Jideytro is also being evaluated as a first-line option.
“The rapid progression of Jideytro from development to approval reflects both the strength of the underlying science and the urgent need for additional effective treatments,” GSK Chief Scientific Officer Tony Wood noted, adding that this approval supports their strategy to pursue assets with validated targets aimed at enhancing treatment standards.
Arrowhead challenges Ionis in triglyceride therapies
In a competitive twist, Arrowhead Pharmaceuticals is poised to disrupt the triglyceride drug market shortly after Ionis received FDA approval for its drug Tryngolza. Arrowhead’s Redemplo has just completed Phase 3 trials showing it met all primary and secondary endpoints, including a remarkable 78% reduction in pancreatitis rates compared to placebo and an 80% decrease in triglyceride levels after one year. The company plans to seek FDA approval by the end of the year, positioning Redemplo as a direct competitor to Tryngolza. Notably, Ionis previously alleged that Arrowhead breached its mRNA technology patent to develop Redemplo.
Uncertainty surrounds Lilly's triple-G drug heart benefits
Eli Lilly reported positive results for its next-generation obesity drug, retatrutide, in a Phase 3 study, where significant weight loss was observed. However, the cardiovascular benefits of this treatment remain ambiguous, as secondary endpoint analyses did not show a statistically significant reduction in major cardiovascular events among patients, a limitation attributed to the study's design.